Anavex Life Sciences Corp (AVXL)

[XenaLives]

A 24 week study of a drug that seriously alters body chemistry is not long enough.

This 52 week Japanese study tells another story:

Results
In total, 203 patients entered the study, and 142 completed the 52-week treatment. Adverse events (AEs) occurred in 78.3% of patients, with nasopharyngitis (20.7%) and dyskinesias (17.7%) as the most common; serious AEs occurred in 17.2%, causing discontinuation in 10.8%. At Week 52, the mean daily ON-time without troublesome dyskinesias increased from baseline by 1.42 h. Change from baseline in mean daily OFF-time was -1.40 h, and that in the UPDRS Part III score in the ON-phase was -6.20.

https://www.jns-journal.com/article/S0022-510X(20)30349-X/fulltext

"All drugs have more or less side effects"

They have side effects when they use the whack-a-mole symptomatic treatment approach. Suppression of symptoms is a dangerous standard for treatment success, especially when there is no long term safety testing done.